Boehringer Ingelheim Vetmedica Inc. (BIVI) has closed a deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the United States, Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens the company's position as a leading vaccine supplier.
"We'll be expanding our business significantly, in fact, doubling our sales in the United States," said George Heidgerken, BIVI president.
The cattle vaccines included in the acquisition include the Triangle®, Pyramid® and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium). The dairy portfolio includes the key brands Today® and Tomorrow®.
"With regard to the brands we are acquiring, it's business as usual," Heidgerken added. "The producers and veterinarians and distributors who handle and benefit from these wonderful brands will really see no significant change."
Reprinted from AgWired.com